Abstract
BackgroundCanakinumab (CAN) is a fully human monoclonal antibody targeting IL-1β, a key cytokine in the pathogenesis of periodic fever syndromes (PFS) including familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have